肝胆相照论坛

标题: 中国针对乙肝的全面干预措施的一揽子投资案例:有助于国 [打印本页]

作者: StephenW    时间: 2021-3-5 19:10     标题: 中国针对乙肝的全面干预措施的一揽子投资案例:有助于国


Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning
Shevanthi Nayagam, Polin Chan, Kun Zhao, Elisa Sicuri, Xiaochun Wang, Jidong Jia, Lai Wei, Nick Walsh, Lance E Rodewald, Guomin Zhang ... Show more
Clinical Infectious Diseases, Volume 72, Issue 5, 1 March 2021, Pages 743–752, https://doi.org/10.1093/cid/ciaa134
Published:
07 April 2020
Article history

    pdfPDF
    Split View
    Cite
    Permissions Icon Permissions
    Share

Abstract
Background

In 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world’s population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of HBV interventions.
Methods

A dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal perspective, incorporating costs of management of end-stage liver disease and lost productivity costs.
Results

Despite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions is likely to have a positive return on investment to society of US$1.57 per US dollar invested.
Conclusions

Increases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-world example of how applied modeling can support national dialog and inform policy planning.
hepatitis B, antiviral treatment, investment case, China, modeling
Topic:

    hepatitis b antiviral agents china hepatitis b, chronic investments hepatitis b virus public health medicine viruses case finding prevention


作者: StephenW    时间: 2021-3-5 19:10

中国针对乙肝的全面干预措施的一揽子投资案例:有助于国家战略规划的应用模型
Shevanthi Nayagam,Polin Chan,赵坤,Elisa Sicuri,王晓春,贾继东,赖玮,Nick Walsh,Lance E Rodewald,张国敏...显示更多
临床传染病,第21卷,第5期,2021年3月1日,第743-752页,https://doi.org/10.1093/cid/ciaa134
发布时间:
2020年4月7日
文章历史

    PDF格式
    拆分视图
    引用
    权限图标权限
    分享

抽象的
背景

2016年,批准了首个全球病毒性肝炎消灭目标。据估计,世界上患有慢性乙型肝炎病毒(HBV)感染的人口中有三分​​之一生活在中国,肝癌是导致死亡的第六大原因,但是一线抗病毒治疗的覆盖率很低。 2015年,中国是最早针对病毒性肝炎采取新方法的咨询程序的国家之一。我们为扩大一揽子HBV干预措施的规模提出了投资案例。
方法

建立了乙肝病毒动态仿真模型,并用于模拟中国乙肝病毒的流行。我们从社会角度评估了一套全面的预防和治疗干预措施的影响,成本和投资回报,其中包括晚期肝病的管理成本和生产力损失成本。
结果

尽管自1992年以来在历史上扩大了疫苗接种规模,但到2030年,仍将有6,000万人感染HBV,预计将有1000万人死于HBV,其中包括2015年至2030年之间将有570万人死于HBV相关的癌症。通过积极的病例发现和最佳的抗病毒治疗方案,减少了210万。一揽子干预措施可能会为社会带来每1美元投资1.57美元的正投资回报。
结论

在接下来的几十年中,与HBV相关的死亡人数的增加对中国构成了重大的公共卫生威胁。为减轻这种风险,需要积极寻找病例并获得最佳抗病毒治疗。这种投资案例方法提供了一个实际示例,说明应用建模如何支持国家对话并为政策规划提供信息。
乙肝,抗病毒治疗,投资案例,中国,模型
话题:

    乙肝抗病毒药中国乙肝,长期投资乙肝病毒公共卫生医学病毒病例发现预防
作者: StephenW    时间: 2021-3-5 19:11

https://academic.oup.com/cid/article/72/5/743/5817057




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5